Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market Evolution - Technavio

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global epinephrine autoinjector market size is estimated to grow by USD 2.44 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 10.59% during the forecast period. Increasing prevalence of allergies is driving market growth, with a trend towards frequent product launches due to government pressure on vendors. However, product recalls and regulatory issues poses a challenge. Key market players include Adamis Pharmaceuticals Corp., ALK Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., BIOPROJET, Crossject, Halozyme Therapeutics Inc., kaleo Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

The Epinephrine Autoinjector market is witnessing significant trends due to the rising acceptance and increased awareness of these life-saving devices. These handheld devices, also known as epinephrine pens or Epis, are used for self administration during acute anaphylactic reactions caused by allergic diseases such as insect bites or stings. Epinephrine, also known as adrenaline, is a vital medication that counteracts the effects of severe allergic responses by constricting blood vessels and increasing blood flow. Healthcare professionals recommend epinephrine autoinjectors for prompt intervention during anaphylactic shock. The market is seeing in demand for pre-filled, specific dose autoinjectors, including needle-free injectors and innovative technologies. Consumer preference for convenient and user-friendly devices is driving the market. Companies like Amphastar Pharmaceuticals are introducing generic versions to cater to the increasing demand and decreasing the burden of allergies. However, recurring product recalls and the rate of diagnosis remain challenges. Digital health platforms and autoinjector training are essential to improve patient awareness and ensure proper usage. 

The US epinephrine autoinjector market is expected to experience several new product launches in the upcoming years due to increased pressure from the US government for FDA approval of generic alternatives to leading brands like Viatriss EpiPen. This follows the price increase of Viatriss EpiPen, prompting US Governor Margaret Wood Hassan to advocate for more options. Companies such as Bausch Health and ALK Abello, with significant European market presence, may enter the US market in response to this initiative. For instance, Teva Pharmaceutical Industries launched their AJOVY in the prefilled YpsoMate 2 in March 2020. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

• The Epinephrine Autoinjector market faces challenges in ensuring accurate dosage for various age groups during acute anaphylactic reactions caused by allergic diseases, such as insect bites or stings. Healthcare professionals emphasize the importance of prompt intervention with epinephrine, also known as Adrenaline, as a life-saving medication for severe allergic reactions. Epinephrine autoinjectors, like epipens and epinephrine pens, are handheld devices that provide convenience and consumer preference for self-administration. However, challenges persist in the form of recurring product recalls, rising acceptance of generic goods from companies like Amphastar Pharmaceuticals, and increasing awareness of innovative technologies like needle-free injectors. Digital health platforms and autoinjector training aim to improve patient awareness and counteract the burden of allergies, while pre-filled, specific dose epinephrine autoinjectors continue to be essential for bronchodilator effects that improve blood flow and counteract anaphylactic shock.
• The epinephrine autoinjector market has encountered challenges due to product recalls and regulatory hurdles. FDA approval for these devices has been a lengthy process, enabling Viatris to dominate the US market. Following Sanofi's exit, Viatris held a monopoly, partly due to the FDA's limited approval of competitors' products and partly because Impax Laboratories (now Amneal Pharmaceuticals) lacked an automated manufacturing facility for generic Adrenaclick supply. Given the critical importance of accurate epinephrine dose delivery during anaphylactic shock emergencies, product recalls are a necessary response.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This epinephrine autoinjector market report extensively covers market segmentation by

1. Type 
• 1.1 0.30gm
• 1.2 0.15gm
• 1.3 0.50gm
2. End-user 
• 2.1 Hospitals
• 2.2 clinics
• 2.3 Homecare
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)
4. Age Group

1.1 0.30gm- The global epinephrine autoinjector market for the 0.30gm dosage segment is projected to experience significant growth due to increasing sales of generic options. Amneal Pharmaceuticals' Adrenaclick and Viatris' upcoming generic EpiPen have gained traction following price hikes by key players. In Europe, market share for Viatris may decline due to the availability of multiple brands. The gradual price increases by Viatris and the exit of competitors have encouraged research and development of alternatives, ensuring market expansion for epinephrine autoinjectors in the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

Epinephrine autoinjectors are handheld devices used to deliver a pre-measured dose of epinephrine during acute anaphylactic reactions. These injectors are essential for individuals with allergic diseases, particularly those prone to severe allergic responses from insect bites or stings. The dosage in epinephrine autoinjectors varies, but they are typically designed for use by individuals or their caregivers, making them accessible during emergencies. Epinephrine, also known as adrenaline, is a vital medication for reversing anaphylaxis, a life-threatening allergic response. Innovative technologies have led to the development of needle-free injectors and generic epinephrine autoinjectors, increasing acceptance and accessibility in the healthcare industry. Epinephrine autoinjectors come in different brands like epinephrine pens and EpiPens, catering to various age groups.

Market Research Overview

Epinephrine autoinjectors, also known as epinephrine pens or EpiPens, are handheld devices that deliver a specific dose of epinephrine, a life-saving medication for individuals experiencing acute anaphylactic reactions due to allergic diseases such as insect stings or food allergies. These devices are essential for prompt intervention during severe allergic responses, counteracting the effects of narrowing blood vessels and decreased blood flow caused by anaphylaxis. The market for epinephrine autoinjectors is witnessing increasing acceptance and awareness, driven by the convenience and consumer preference for self-administration devices. The rising burden of allergies and the need for prompt intervention have led to the development of innovative technologies, including needle-free injectors and digital health platforms for autoinjector training. The market includes pre-filled epinephrine autoinjectors in various dosages for different age groups, with both branded and generic versions available. However, recurring product recalls and the rate of diagnosis remain challenges for the industry. Epinephrine, also known as adrenaline, is a vital medication used to treat anaphylactic shock, a potentially fatal allergic reaction.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Type
• 0.30gm
• 0.15gm
• 0.50gm
• End-user
• Hospitals
• Clinics
• Homecare
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)
• Age Group

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio